Company Dossier · Health Care
Cencora
- S&P 500
- Russell 1000
What Cencora is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $333 billion, up 5.1% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $4.06 billion, up 256% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.76 billion, up 27% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to September 30, 2025: $0.44 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to September 30, 2025: $4.51 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 5, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 4 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed November 25, 2025): 0 risk factors added, 2 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $4.4 million on the open market.SEC Form 4
- 1,354 institutional managers reported a position at June 30, 2026 (−84 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 19 (10 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Cencora is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending79th pct
- Debt raised43rd pct
- Buybacks vs capex—
- Hiring filings48th pct
- Deals and private raises40th pct
- Patent publications7th pct
- + Capital spending
- − Patent publications
- − Deals and private raises
Confident ↔ Hedging
Confident
- Call sentiment65th pct
- Call confidence74th pct
- Guidance changes70th pct
- Risk factors added82nd pct
- Insider open-market trades83rd pct
- + Guidance changes
- + Insider open-market trades
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver15th pct
- Stress filings43rd pct
Credit
How these are built →Cencora's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$11.7B
- Due within a year $0.3B
- Longer term $11.4B
- Default point $6.0B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
$3.0B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 10, 2026 | $500M | 3.950% | 2029 (3y) | +48bp | 3.993% |
| Feb 10, 2026 | $500M | 4.600% | 2033 (7y) | +70bp | 4.609% |
| Feb 10, 2026 | $1B | 4.900% | 2036 (10y) | +80bp | 4.943% |
| Feb 10, 2026 | $500M | 4.250% | 2030 (5y) | +60bp | 4.296% |
| Feb 10, 2026 | $500M | 5.650% | 2056 (30y) | +90bp | 5.688% |
| May 15, 2025 | €500M | 3.625% | 2032 (7y) | +129bp | 3.665% |
| May 15, 2025 | €500M | 2.875% | 2028 (3y) | +94bp | 2.889% |
| Dec 2, 2024 | $700M | 5.150% | 2035 (10y) | +97bp | 5.158% |
| Dec 2, 2024 | $500M | 4.625% | 2027 (3y) | +55bp | 4.691% |
| Dec 2, 2024 | $600M | 4.850% | 2029 (5y) | +77bp | 4.857% |
| Feb 5, 2024 | $500M | 5.125% | 2034 (10y) | +98bp | 5.142% |
From the pricing term sheets Cencora filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Cencora, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralCencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow (NYSE:COR)
seekingalpha.com · via Marketaux · Oct 6, 2026
- NeutralCencora Inc (COR) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (CENCORA, INC.)third_quarter 2026 · $0.4 million
- Oct 20, 2026LobbyingLobbying report (THE DUBERSTEIN GROUP INC.)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BROWNSTEIN HYATT FARBER SCHRECK, LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MONUMENT ADVOCACY)third_quarter 2026 · $0.0 million
- Oct 20, 2026LobbyingLobbying report (INLET STRATEGIES)third_quarter 2026 · $0.0 million
- Oct 13, 2026LobbyingLobbying report (KOUNTOUPES DENHAM CARR & REID, LLC)third_quarter 2026 · $0.1 million
- Sep 25, 20268-KDirector or officer changeItem 5.02
- Sep 10, 2026Trademark
- Aug 14, 20268-KDirector or officer changeItem 5.02
- Aug 5, 20268-KMaterial agreement signedItem 1.01
- Jul 21, 2026LobbyingLobbying report (HARBINGER STRATEGIES, LLC)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (KOUNTOUPES DENHAM CARR & REID, LLC)second_quarter 2026 · $0.1 million
- Jun 25, 2026Trademark
- Jun 15, 20268-KDirector or officer changeItem 5.02
- May 29, 20268-KDirector or officer changeItem 5.02
- Mar 17, 20268-KDirector or officer changeItem 5.02
- Mar 6, 20268-KShareholder vote resultsItem 5.07
- Feb 13, 20268-KMaterial agreement signedItem 1.01
- Jan 22, 20268-KDirector or officer changeItem 5.02
- Jan 16, 20268-KMaterial agreement signedItem 1.01
- Nov 25, 202510-KAnnual report (10-K)0 risk factors added, 2 removed
- Sep 11, 2025Trademark
- Sep 11, 2025Trademark
- Sep 11, 2025Trademark
- Sep 9, 20258-KMaterial agreement signedItem 1.01
- Aug 27, 20258-KDirector or officer changeItem 5.02
- Jul 3, 20258-KMaterial agreement signedItem 1.01
- Jun 6, 20258-KMaterial agreement signedItem 1.01
- Jun 6, 20258-KMaterial agreement terminatedItem 1.02
- May 28, 20258-KDirector or officer changeItem 5.02
- May 22, 20258-KMaterial agreement signedItem 1.01
- Mar 10, 20258-KShareholder vote resultsItem 5.07
- Feb 10, 20258-KMaterial agreement signedItem 1.01
- Jan 22, 20258-KDirector or officer changeItem 5.02
- Jan 2, 20258-KAcquisition or sale completedItem 2.01
- Dec 10, 20248-KMaterial agreement signedItem 1.01
- Nov 27, 20248-KMaterial agreement signedItem 1.01
- Nov 26, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
- Nov 19, 2024PatentPatent granted: DOSE TRACKING DEVICEUS 12144783
- Nov 21, 202310-KAnnual report (10-K)4 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| McKesson Corporation MCK | $411B | $6.4B | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Henry Schein HSIC | $13.6B | $0.6B | Jun 27, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| UnitedHealth Group UNH | $450B | $23.6B | Jun 30, 2026 |
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |